The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia
Authors:
- 23 December 2009
- journal article
- research article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 25 (2) , 187-190
Abstract
Objective: We compared the effects of haloperidol and three atypical antipsychotics (risperidone, olanzapine, and aripiprazole) on nicotine dependence in schizophrenic patients.Methods: One hundred and thirty nine schizophrenic patients, who began using antipsychotic medication, were assessed for severity of nicotine dependence and for cigarette craving at baseline and following 8 weeks of treatment using the Fagerström Tolerance Questionnaire (FTQ) and a Likert‐style, seven point, visual‐analogue rating scale.Results: Nicotine dependence increased in the haloperidol group, but not in atypical antipsychotics groups. Patients treated with aripiprazole showed a reduction both in nicotine dependence and cigarette craving.Conclusions: The effects of aripiprazole, a partial agonist of the dopamine D2 receptor, may reduce the severity of nicotine dependence in schizophrenic patients. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 13 references indexed in Scilit:
- Subjective, cognitive/psychomotor, and physiological effects of aripiprazole in Chinese light and heavy smokersDrug and Alcohol Dependence, 2009
- Treatment of tobacco dependence: integrating recent progress into practiceCanadian Medical Association Journal, 2007
- Smoking and Schizophrenia: Is Symptom Profile Related to Smoking and which Antipsychotic Medication is of Benefit in Reducing Cigarette use?Australian & New Zealand Journal of Psychiatry, 2006
- Nicotine use in schizophrenia: The self medication hypothesesNeuroscience & Biobehavioral Reviews, 2005
- Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerabilityClinical Therapeutics, 2004
- What's atypical about atypical antipsychotic drugs?Current Opinion in Pharmacology, 2004
- Treatment of Schizophrenia and Comorbid Substance Use DisorderCurrent Drug Targets-CNS & Neurological Disorders, 2002
- A neurobiological basis for substance abuse comorbidity in schizophreniaBiological Psychiatry, 2001
- Smoking Habits, Current Symptoms, and Premorbid Characteristics of Schizophrenic Patients in Nithsdale, ScotlandAmerican Journal of Psychiatry, 1999
- Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatmentAddictive Behaviors, 1978